Reports Q2 revenue $18.08M vs. $18.68M last year. “In just over a year, we have made great strides in increasing revenue, reducing expenses, and driving the company towards profitability,” said Mark Strobeck, Ph.D., Rockwell Medical’s President and CEO. “By acquiring Evoqua Water Technologies’ profitable, revenue-generating hemodialysis concentrates business, we now expect to be profitable in the fourth quarter of 2023 and going forward. This puts Rockwell Medical in a stronger, more stable financial position to further enhance shareholder value and pursue additional growth opportunities.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RMTI:
- RMTI Upcoming Earnings Report: What to Expect?
- Rockwell Medical price target raised to $11 from $9 at H.C. Wainwright
- Rockwell Medical raises 2023 revenue view to $82M-$86M from $78M-$82M
- Rockwell Medical acquires hemodialysis concentrates business from Evoqua Water
- Rockwell Medical announces 3-year co-promotional pact with B. Braun Medical
